Brief: IO Biotech Announces Acceptance Of Abstracts To Be Presented At The 2025 American Association For Cancer Research (AACR) Annual Meeting
Brief: IO Biotech Receives Nasdaq Notice For Minimum Bid Price Non-Compliance
Brief: Io Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank
Brief: IO Biotech Says Io102-Io103 Combo With Keytruda Shows 55% Orr In Nsclc
Brief: IO Biotech Expands Senior Leadership Team To Progress Commercialization Readiness
Brief: IO Biotech Announces 2023 Fourth-Quarter And Year-End Results
Brief: Io Biotech Announces First Patient Dosed In Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
Brief: IO Biotech Appoints Helen Collins To Its Board Of Directors
Brief: IO Biotech Q3 basic EPS USD -0.43
Brief: IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
Brief: IO Biotech Announces Preliminary Data From Phase 2 Trial Evaluating Io102-Io103 In Combination With Pembrolizumab
Brief: Kurma Partners Reports 17.18% Passive Stake In Io Biotech As Of August 31
Brief: Io Biotech Inc Says Files Prospectus Related To Resale, From Time To Time By The Selling Stockholders Of Up To 74.1 Mln Shares Of Common Stock
Brief: IO Biotech Q2 basic EPS USD -0.74.
Brief: IO Biotech Appoints Heidi Hunter To Its Board Of Directors
Brief: Io Biotech Announces $75 Million Private Placement Financing
Brief: IO Biotech Announces Achievement Of Phase 3 Clinical Trial Recruitment Milestone
Brief: Io Biotech Announces 2023 First-Quarter Results
Brief: Io Biotech Announces 2022 Fourth-Quarter And Year-End Results